Dynamics of Bromodeoxyuridine Incorporation into DNA of Squamous Carcinoma Cells During Mid and Late Logarithmic Growth
dc.contributor.author | Maybaum, Jonathan | en_US |
dc.contributor.author | Wagner, John G. | en_US |
dc.contributor.author | Ensminger, William D. | en_US |
dc.contributor.author | Carey, Thomas E. | en_US |
dc.contributor.author | Shapira, Amnon | en_US |
dc.date.accessioned | 2006-09-08T19:21:12Z | |
dc.date.available | 2006-09-08T19:21:12Z | |
dc.date.issued | 1988-08 | en_US |
dc.identifier.citation | Shapira, Amnon; Wagner, John G. ***MISSING END TAG*** Ira S.; Maybaum, Jonathan Phillip L.; Ensminger, William D.; Carey, Thomas E.; (1988). "Dynamics of Bromodeoxyuridine Incorporation into DNA of Squamous Carcinoma Cells During Mid and Late Logarithmic Growth." Pharmaceutical Research 5(8): 518-522. <http://hdl.handle.net/2027.42/41525> | en_US |
dc.identifier.issn | 0724-8741 | en_US |
dc.identifier.issn | 1573-904X | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/41525 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=3244661&dopt=citation | en_US |
dc.description.abstract | Head and neck squamous carcinoma cell lines, UM-SCC 1, 5, 9, 11B, and 14B, were exposed in vitro to bromodeoxyuridine (BUdR) during logarithmic growth to determine the effects of drug concentration (0.01 to 10 µ M ) and duration of exposure (3, 7, and 10 days) on cell growth and on incorporation of BUdR into DNA. Concentrations of less than 1.0 µ M were not growth inhibitory except with UM-SCC-11B. After 10 days of exposure to 5 µ M BUdR, survival fractions for all lines ranged from 2 to 65% of controls. Replacement of thymidine by BUdR in DNA was assessed by gas chromatography/mass spectroscopy. Percentage replacement (% R) was described by the equation % R = 100 ( C/t ) s /[( C/t ) 50 s + ( C/t ) s ], where C is the concentration of BUdR (µ M) , t is the time in days, s is a constant, and ( C/t ) 50 is a constant corresponding to % R = 50%. BUdR incorporation reached a time-and concentration-dependent maximum that, after 3 to 7 days of culture in 10 µ M BUdR, ranged from 30 to 60% R. Subsequently, % R declined with time even though the cells were fed daily with fresh BUdR-containing medium. | en_US |
dc.format.extent | 626201 bytes | |
dc.format.extent | 3115 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Kluwer Academic Publishers-Plenum Publishers; Plenum Publishing Corporation ; Springer Science+Business Media | en_US |
dc.subject.other | Medical Law | en_US |
dc.subject.other | Pharmacy | en_US |
dc.subject.other | Bromodeoxyuridine (BUdR) Incorporation in Vitro | en_US |
dc.subject.other | Pharmacology/Toxicology | en_US |
dc.subject.other | Biomedicine | en_US |
dc.subject.other | Biochemistry, General | en_US |
dc.subject.other | Squamous Carcinoma Cells | en_US |
dc.subject.other | Biomedical Engineering | en_US |
dc.subject.other | Thymidine Replacement | en_US |
dc.subject.other | Kinetics of Replacement | en_US |
dc.title | Dynamics of Bromodeoxyuridine Incorporation into DNA of Squamous Carcinoma Cells During Mid and Late Logarithmic Growth | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Department of Pharmacology, The University of Michigan Medical School, Ann Arbor, Michigan, 48109; College of Pharmacy, The University of Michigan Medical School, Ann Arbor, Michigan, 48109; Upjohn Center for Clinical Pharmacology, The University of Michigan Medical School, Ann Arbor, Michigan, 48109; Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, Michigan, 48109 | en_US |
dc.contributor.affiliationum | The University of Michigan Medical School, Ann Arbor, Michigan, 48109; Cancer Research Laboratory, 6020 KHRI, The University of Michigan, Box 0506, 1301 East Ann Street, Ann Arbor, Michigan, 48109-0506 | en_US |
dc.contributor.affiliationum | The University of Michigan Medical School, Ann Arbor, Michigan, 48109; Department of Otolaryngology, Barzilai Medical Center, Ashkelov, 73606, Israel | en_US |
dc.contributor.affiliationum | Department of Pharmacology, The University of Michigan Medical School, Ann Arbor, Michigan, 48109; Upjohn Center for Clinical Pharmacology, The University of Michigan Medical School, Ann Arbor, Michigan, 48109; Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, Michigan, 48109 | en_US |
dc.contributor.affiliationum | Department of Pharmacology, The University of Michigan Medical School, Ann Arbor, Michigan, 48109; Upjohn Center for Clinical Pharmacology, The University of Michigan Medical School, Ann Arbor, Michigan, 48109 | en_US |
dc.contributor.affiliationumcampus | Ann Arbor | en_US |
dc.identifier.pmid | 3244661 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/41525/1/11095_2004_Article_306239.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1023/A:1015925509778 | en_US |
dc.identifier.source | Pharmaceutical Research | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.